Increase of β-endorphin secretion by agmatine is induced by activation of imidazoline I2A receptors in adrenal gland of rats

Chin Hong Chang, Hung Tsung Wu, Kai Chun Cheng, Hung Jung Lin, Juei Tang Cheng

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Activation of imidazoline I2 receptor (I2R) by agmatine in adrenal gland lowers plasma glucose through increment in β-endorphin release to stimulate the opioid μ-receptor in streptozotocin-induced diabetic rats (STZ rats). However, the subtype of I2R for agmatine-induced blood glucose lowering effect remains obscure. In the present study, agmatine treatment increased β-endorphin secretion and this effect was blocked by I2R antagonist (BU224) in the isolated adrenal medulla. We further used amiloride, an established blocker of I2AR, to identify the subtype of I2R in adrenal gland. Results showed that agmatine-induced β-endorphin release from adrenal gland was blocked by 0.1 μM amiloride indicating the mediation of I2AR. It was further confirmed that agmatine-induced plasma glucose decrement and plasma β-endorphin increment in STZ rats were blocked by amiloride. However, amiloride failed to modify the action of guanidine, an agonist of I2BR, at the sufficient dose to block β-endorphin secretion. Taken together, the increase of plasma β-endorphin by agmatine in STZ rats through activation of imidazoline I2R was mainly induced by the I2A subtype located in adrenal gland. Thus, imidazoline I2A receptor in the adrenal gland might be applied as a new target for induction of opioid secretion.

Original languageEnglish
Pages (from-to)297-299
Number of pages3
JournalNeuroscience Letters
Volume468
Issue number3
DOIs
Publication statusPublished - Jan 14 2010
Externally publishedYes

Fingerprint

Imidazoline Receptors
Agmatine
Endorphins
Adrenal Glands
Amiloride
Streptozocin
Glucose
Adrenal Medulla
Guanidine
Opioid Receptors
Opioid Analgesics
Blood Glucose

Keywords

  • β-Endorphin
  • Adrenal gland
  • Agmatine
  • Amiloride
  • Diabetes
  • Imidazoline receptor

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Increase of β-endorphin secretion by agmatine is induced by activation of imidazoline I2A receptors in adrenal gland of rats. / Chang, Chin Hong; Wu, Hung Tsung; Cheng, Kai Chun; Lin, Hung Jung; Cheng, Juei Tang.

In: Neuroscience Letters, Vol. 468, No. 3, 14.01.2010, p. 297-299.

Research output: Contribution to journalArticle

Chang, Chin Hong ; Wu, Hung Tsung ; Cheng, Kai Chun ; Lin, Hung Jung ; Cheng, Juei Tang. / Increase of β-endorphin secretion by agmatine is induced by activation of imidazoline I2A receptors in adrenal gland of rats. In: Neuroscience Letters. 2010 ; Vol. 468, No. 3. pp. 297-299.
@article{9e2f5a6d7ac148aca8ff62dd38e4df06,
title = "Increase of β-endorphin secretion by agmatine is induced by activation of imidazoline I2A receptors in adrenal gland of rats",
abstract = "Activation of imidazoline I2 receptor (I2R) by agmatine in adrenal gland lowers plasma glucose through increment in β-endorphin release to stimulate the opioid μ-receptor in streptozotocin-induced diabetic rats (STZ rats). However, the subtype of I2R for agmatine-induced blood glucose lowering effect remains obscure. In the present study, agmatine treatment increased β-endorphin secretion and this effect was blocked by I2R antagonist (BU224) in the isolated adrenal medulla. We further used amiloride, an established blocker of I2AR, to identify the subtype of I2R in adrenal gland. Results showed that agmatine-induced β-endorphin release from adrenal gland was blocked by 0.1 μM amiloride indicating the mediation of I2AR. It was further confirmed that agmatine-induced plasma glucose decrement and plasma β-endorphin increment in STZ rats were blocked by amiloride. However, amiloride failed to modify the action of guanidine, an agonist of I2BR, at the sufficient dose to block β-endorphin secretion. Taken together, the increase of plasma β-endorphin by agmatine in STZ rats through activation of imidazoline I2R was mainly induced by the I2A subtype located in adrenal gland. Thus, imidazoline I2A receptor in the adrenal gland might be applied as a new target for induction of opioid secretion.",
keywords = "β-Endorphin, Adrenal gland, Agmatine, Amiloride, Diabetes, Imidazoline receptor",
author = "Chang, {Chin Hong} and Wu, {Hung Tsung} and Cheng, {Kai Chun} and Lin, {Hung Jung} and Cheng, {Juei Tang}",
year = "2010",
month = "1",
day = "14",
doi = "10.1016/j.neulet.2009.11.018",
language = "English",
volume = "468",
pages = "297--299",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Increase of β-endorphin secretion by agmatine is induced by activation of imidazoline I2A receptors in adrenal gland of rats

AU - Chang, Chin Hong

AU - Wu, Hung Tsung

AU - Cheng, Kai Chun

AU - Lin, Hung Jung

AU - Cheng, Juei Tang

PY - 2010/1/14

Y1 - 2010/1/14

N2 - Activation of imidazoline I2 receptor (I2R) by agmatine in adrenal gland lowers plasma glucose through increment in β-endorphin release to stimulate the opioid μ-receptor in streptozotocin-induced diabetic rats (STZ rats). However, the subtype of I2R for agmatine-induced blood glucose lowering effect remains obscure. In the present study, agmatine treatment increased β-endorphin secretion and this effect was blocked by I2R antagonist (BU224) in the isolated adrenal medulla. We further used amiloride, an established blocker of I2AR, to identify the subtype of I2R in adrenal gland. Results showed that agmatine-induced β-endorphin release from adrenal gland was blocked by 0.1 μM amiloride indicating the mediation of I2AR. It was further confirmed that agmatine-induced plasma glucose decrement and plasma β-endorphin increment in STZ rats were blocked by amiloride. However, amiloride failed to modify the action of guanidine, an agonist of I2BR, at the sufficient dose to block β-endorphin secretion. Taken together, the increase of plasma β-endorphin by agmatine in STZ rats through activation of imidazoline I2R was mainly induced by the I2A subtype located in adrenal gland. Thus, imidazoline I2A receptor in the adrenal gland might be applied as a new target for induction of opioid secretion.

AB - Activation of imidazoline I2 receptor (I2R) by agmatine in adrenal gland lowers plasma glucose through increment in β-endorphin release to stimulate the opioid μ-receptor in streptozotocin-induced diabetic rats (STZ rats). However, the subtype of I2R for agmatine-induced blood glucose lowering effect remains obscure. In the present study, agmatine treatment increased β-endorphin secretion and this effect was blocked by I2R antagonist (BU224) in the isolated adrenal medulla. We further used amiloride, an established blocker of I2AR, to identify the subtype of I2R in adrenal gland. Results showed that agmatine-induced β-endorphin release from adrenal gland was blocked by 0.1 μM amiloride indicating the mediation of I2AR. It was further confirmed that agmatine-induced plasma glucose decrement and plasma β-endorphin increment in STZ rats were blocked by amiloride. However, amiloride failed to modify the action of guanidine, an agonist of I2BR, at the sufficient dose to block β-endorphin secretion. Taken together, the increase of plasma β-endorphin by agmatine in STZ rats through activation of imidazoline I2R was mainly induced by the I2A subtype located in adrenal gland. Thus, imidazoline I2A receptor in the adrenal gland might be applied as a new target for induction of opioid secretion.

KW - β-Endorphin

KW - Adrenal gland

KW - Agmatine

KW - Amiloride

KW - Diabetes

KW - Imidazoline receptor

UR - http://www.scopus.com/inward/record.url?scp=72549092423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72549092423&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2009.11.018

DO - 10.1016/j.neulet.2009.11.018

M3 - Article

VL - 468

SP - 297

EP - 299

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 3

ER -